Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients
Authors:
- 15 July 2021
- journal article
- research article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 54 (4) , 861-872
Abstract
Purpose Iron-based phosphate binders, including ferric citrate hydrate (FCH) and sucroferric oxyhydroxide (SFOH), have been used for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. However, the long-term efficacy and safety of these agents have not yet been clearly elucidated. Methods Laboratory data of 56 hemodialysis patients who had been prescribed either FCH (n = 33) or SFOH (n = 23) were retrospectively examined. Results We showed that both FCH and SFOH significantly and consistently decreased serum phosphate concentrations in the patients undergoing maintenance hemodialysis during the 36-month observation period. Serum levels of calcium, intact parathyroid hormone, as well as hemoglobin levels were unaltered. No overshoot of parameters of iron metabolism, such as transferrin saturation and serum ferritin levels, was observed, and serum ferritin level remained under 300 ng/mL in most patients. A trend towards decrease in the doses of erythropoiesis-stimulating agents used and frequency of intravenous iron use was observed in both treatment groups. No severe adverse drug reactions were observed in either the patients receiving FCH or SFOH. Conclusion The results of the present study suggest that the iron-based phosphate binders, FCH and SFOH, decrease serum phosphate concentrations consistently and are safe to use over the long-term in maintenance hemodialysis patients.Keywords
This publication has 30 references indexed in Scilit:
- Prevention and treatment of hyperphosphatemia in chronic kidney diseaseKidney International, 2018
- KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)Kidney International Supplements, 2017
- Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRDJournal of the American Society of Nephrology, 2015
- Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on DialysisJournal of the American Society of Nephrology, 2015
- A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patientsKidney International, 2014
- A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysisNephrology Dialysis Transplantation, 2013
- Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone DisorderTherapeutic Apheresis and Dialysis, 2013
- Phosphate Binder Use and Mortality Among Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of Possible Confounding by Nutritional StatusAmerican Journal of Kidney Diseases, 2012
- Phosphorus Binders and Survival on HemodialysisJournal of the American Society of Nephrology, 2009
- Hyperphosphatemia of chronic kidney diseaseKidney International, 2008